![]()
|
|
||||||||
J. Biol. Chem., Vol. 278, Issue 44, 43846-43854, October 31, 2003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
and AP-1 in the Control of Fibroblast Proliferation and Growth Arrest-specific Gene Expression*


¶
||
**



From the
Department of Biology, York University, Toronto, Ontario M3J 1P3, Canada and the 
Department of Biology, McMaster University, Hamilton, Ontario L8S 1K4, Canada
Chicken embryo fibroblasts (CEF) express several growth arrest-specific (GAS) gene products in G0. In contact-inhibited cells, the expression of the most abundant of these proteins, the p20K lipocalin, is activated at the transcriptional level by C/EBP
. In this report, we describe the role of C/EBP
in CEF proliferation. We show that the expression of a dominant negative mutant of C/EBP
(designated
184-C/EBP
) completely inhibited p20K expression at confluence and stimulated the proliferation of CEF without inducing transformation. Mouse embryo fibroblasts nullizygous for C/EBP
had a proliferative advantage over cells with one or two functional copies of this gene. C/EBP inhibition enhanced the expression of the three major components of AP-1 in cycling CEF, namely c-Jun, JunD, and Fra-2, and stimulated AP-1 activity. In contrast, the over-expression of C/EBP
caused a dramatic reduction in the levels of AP-1 proteins. Therefore, C/EBP
is a negative regulator of AP-1 expression and activity in CEF. The expression of cyclin D1 and cell proliferation were stimulated by the dominant negative mutant of C/EBP
but not in the presence of TAM67, a dominant negative mutant of c-Jun and AP-1. CEF over-expressing c-Jun, and to a lesser extent JunD and Fra-2, did not growth arrest at high cell density and did not express p20K. Therefore, AP-1 interfered with the action of C/EBP
at high cell density, indicating that these factors play opposing roles in the control of GAS gene expression and CEF proliferation.
Received for publication, April 18, 2003 , and in revised form, July 25, 2003.
* This work was made possible by grants from the Natural Sciences and Engineering Research Council of Canada and the Canadian Institutes of Health Research (to P.-A. B.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Present address: Samuel Lunenfeld Institute, Mount Sinai Hospital, Toronto, Ontario M5G 1X5, Canada.
¶ Present address: Cancer Center and Gerontology Center, University of Michigan, Ann Harbor, MI 48109.
|| Present address: Sunnybrook & Women's College Health Sciences Centre, Toronto, Ontario M4N 3M5, Canada.
** Present address: Institut Pasteur, Unité d'Immunologie Virale, Bât. SIDA-Rétrovirus, 28 rue du Dr Roux, 75724 Paris, Cedex 15, France.

To whom correspondence should be addressed. Tel.: 905-525-9140 (ext. 23149); Fax: 905-522-6066; E-mail: abedard{at}mcmaster.ca.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |